Cell cycle and no end

Our knowledge about the molecular circuits regulating the duplication of the genetic material and the subsequent division of a cell into two daughter cells has exploded over the last decade. Aberrations in the regulation of the cell cycle belong to the hallmarks of malignant transformation, leading, in turn, to the development of tumours. After introducing the basics of eukaryotic cell-cycle regulation and describing the four phases of the cell cycle (namely, G1, S, G2 and M) in more detail, alterations of key components of the cell-cycle machinery in human malignancies and their functional consequences are presented. Principally, deregulation of the cell cycle can be caused by unrestricted activity of cell-cycle promoting factors (many oncogenes fall into this class) or by inactivation of inhibitory factors (many tumour suppressor genes belong to this class). Both types of deregulation have been described in human tumours and are discussed in detail. Perspectives concerning the translation of this knowledge into daily routine practice and future applications are discussed at the end. The molecular mechanisms of actual cell division (sister chromatid segregation and cytokinesis) are mentioned only briefly.

[1]  David Beach,et al.  p21 is a universal inhibitor of cyclin kinases , 1993, Nature.

[2]  S. Elledge,et al.  The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases , 1993, Cell.

[3]  S. Reed,et al.  Deregulated cyclin E induces chromosome instability , 1999, Nature.

[4]  K. Sugimachi,et al.  Significance of cyclin B1 expression as an independent prognostic indicator of patients with squamous cell carcinoma of the esophagus. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[5]  G. Hannon,et al.  A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4 , 1993, Nature.

[6]  G. Melino,et al.  p73: Friend or foe in tumorigenesis , 2002, Nature Reviews Cancer.

[7]  M. Molinari Cell cycle checkpoints and their inactivation in human cancer , 2000, Cell proliferation.

[8]  Johannes Gerdes,et al.  The Ki‐67 protein: From the known and the unknown , 2000, Journal of cellular physiology.

[9]  J. Gerdes,et al.  Ki-67 immunoexpression is a robust marker of proliferative cells in the rat. , 1997, Laboratory investigation; a journal of technical methods and pathology.

[10]  M.-H. Lee,et al.  Contributions in the domain of cancer research: Review¶Negative regulators of cyclin-dependent kinases and their roles in cancers , 2001, Cellular and Molecular Life Sciences CMLS.

[11]  S. Sen,et al.  A putative serine/threonine kinase encoding gene BTAK on chromosome 20q13 is amplified and overexpressed in human breast cancer cell lines , 1997, Oncogene.

[12]  K. Vermeulen,et al.  Cell cycle and apoptosis , 2003, Cell proliferation.

[13]  Su-Jae Lee,et al.  Cell cycle and cancer. , 2003, Journal of biochemistry and molecular biology.

[14]  M. von Knebel Doeberitz,et al.  p16INK4a Immunohistochemistry Improves Interobserver Agreement in the Diagnosis of Cervical Intraepithelial Neoplasia , 2002, The American journal of surgical pathology.

[15]  J. Mandell,et al.  Phosphorylation state-specific antibodies: applications in investigative and diagnostic pathology. , 2003, The American journal of pathology.

[16]  P. Richardson Clinical update: proteasome inhibitors in hematologic malignancies. , 2003, Cancer treatment reviews.

[17]  A. Yang,et al.  On the shoulders of giants: p63, p73 and the rise of p53. , 2002, Trends in genetics : TIG.

[18]  J. Gerdes,et al.  The Ki-67 protein: fascinating forms and an unknown function. , 2000, Experimental cell research.

[19]  G. Hannon,et al.  p15INK4B is a potential effector of TGF-beta-induced cell cycle arrest. , 1994, Nature.

[20]  J. Blow,et al.  Replication licensing--defining the proliferative state? , 2002, Trends in cell biology.

[21]  I. Wong,et al.  Aberrant p15 promoter methylation in adult and childhood acute leukemias of nearly all morphologic subtypes: potential prognostic implications. , 2000, Blood.

[22]  Y. Shiloh ATM and related protein kinases: safeguarding genome integrity , 2003, Nature Reviews Cancer.

[23]  C. Roskelley,et al.  The role of the breast cancer susceptibility gene 1 (BRCA1) in sporadic epithelial ovarian cancer , 2003, Reproductive biology and endocrinology : RB&E.

[24]  F. Mertens,et al.  Abnormal cell cycle regulation in malignancy. , 1999, American journal of clinical pathology.

[25]  G. Peters,et al.  Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer. , 1996, Advances in cancer research.

[26]  Amanda G Paulovich,et al.  When Checkpoints Fail , 1997, Cell.

[27]  J. Herman,et al.  Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. , 1995, Cancer research.

[28]  J. Issa,et al.  Lack of p21(CIP1) DNA methylation in acute lymphocytic leukemia. , 2002, Blood.

[29]  D. Johnson,et al.  Cyclins and cell cycle checkpoints. , 1999, Annual review of pharmacology and toxicology.

[30]  R. Parwaresch,et al.  A closer look at the cell cycle , 2005, Virchows Archiv A.

[31]  D. Sidransky,et al.  p16(MTS-1/CDKN2/INK4a) in cancer progression. , 2001, Experimental cell research.

[32]  R. Poon,et al.  Cyclin A in cell cycle control and cancer , 2002, Cellular and Molecular Life Sciences CMLS.

[33]  R. Wood,et al.  Which DNA polymerases are used for DNA-repair in eukaryotes? , 1997, Carcinogenesis.

[34]  T. Kelly,et al.  Regulation of chromosome replication. , 2000, Annual review of biochemistry.

[35]  A. Ganser,et al.  Aberrant methylation and impaired expression of the p15INK4b cell cycle regulatory gene in chronic myelomonocytic leukemia (CMML) , 2003, Leukemia.

[36]  Jian Kuang,et al.  Aurora B kinase exists in a complex with survivin and INCENP and its kinase activity is stimulated by survivin binding and phosphorylation. , 2002, Molecular biology of the cell.

[37]  H. Gali-Muhtasib,et al.  Modulating cell cycle: current applications and prospects for future drug development. , 2002, Current cancer drug targets.

[38]  A. Yang,et al.  Monoallelically Expressed Gene Related to p53 at 1p36, a Region Frequently Deleted in Neuroblastoma and Other Human Cancers , 1997, Cell.

[39]  Gregory J. Hannon,et al.  pl5INK4B is a potentia| effector of TGF-β-induced cell cycle arrest , 1994, Nature.

[40]  W. Hahn,et al.  Modelling the molecular circuitry of cancer , 2002, Nature Reviews Cancer.

[41]  Tony Hunter,et al.  p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21 , 1994, Cell.

[42]  D O Morgan,et al.  Cyclin-dependent kinases: engines, clocks, and microprocessors. , 1997, Annual review of cell and developmental biology.

[43]  S. Elledge,et al.  Conservation of the Chk1 checkpoint pathway in mammals: linkage of DNA damage to Cdk regulation through Cdc25. , 1997, Science.

[44]  C. D. Edwards,et al.  A novel p16INK4A transcript. , 1995, Cancer research.

[45]  Erich A. Nigg,et al.  Cell division: Mitotic kinases as regulators of cell division and its checkpoints , 2001, Nature Reviews Molecular Cell Biology.

[46]  D. Altieri Validating survivin as a cancer therapeutic target , 2003, Nature Reviews Cancer.

[47]  Stephen J. Elledge,et al.  Cell Cycle Checkpoints: Preventing an Identity Crisis , 1996, Science.

[48]  J. Massagué,et al.  Cloning of p57KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution. , 1995, Genes & development.

[49]  F. McKeon,et al.  Mutations in the p53 homolog p63: allele-specific developmental syndromes in humans. , 2002, Trends in molecular medicine.

[50]  G. Hannon,et al.  Cloning and characterization of murine p16INK4a and p15INK4b genes. , 1995, Oncogene.

[51]  B. Falini,et al.  Proteins encoded by genes involved in chromosomal alterations in lymphoma and leukemia: clinical value of their detection by immunocytochemistry. , 2002, Blood.

[52]  Y. Seo,et al.  Prognostic Significance of p21 and p53 Expression in Gastric Cancer , 2003, The Korean journal of internal medicine.

[53]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[54]  C. Lillo,et al.  The Glial Design of a Teleost Optic Nerve Head Supporting Continuous Growth , 2002, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[55]  S. Carr,et al.  Mammalian Chk2 is a downstream effector of the ATM-dependent DNA damage checkpoint pathway , 1999, Oncogene.

[56]  C. Sherr Cancer Cell Cycles , 1996, Science.

[57]  J. Issa,et al.  Lack of p21CIP1 DNA methylation in acute lymphocytic leukemia , 2002 .

[58]  Sehwan Han,et al.  Prognostic implication of cyclin E expression and its relationship with cyclin D1 and p27Kip1 expression on tissue microarrays of node negative breast cancer , 2003, Journal of surgical oncology.

[59]  F. Miller,et al.  The cellular basis of tumor progression. , 1998, International review of cytology.

[60]  K. Do,et al.  Expression profile of 11 proteins and their prognostic significance in patients with chronic lymphocytic leukemia (CLL) , 2002, Leukemia.

[61]  K. Vermeulen,et al.  The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer , 2003, Cell proliferation.

[62]  A. Carnero,et al.  Targeting the cell cycle for cancer therapy , 2002, British Journal of Cancer.

[63]  R. Douglas,et al.  Genetic models in applied physiology: invited review: effect of oxygen deprivation on cell cycle activity: a profile of delay and arrest. , 2003, Journal of applied physiology.

[64]  H. Nishitani,et al.  Control of DNA replication licensing in a cell cycle , 2002, Genes to cells : devoted to molecular & cellular mechanisms.

[65]  James M. Roberts,et al.  Cloning of p27 Kip1 , a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals , 1994, Cell.

[66]  J. Scholey,et al.  Cell division , 2003, Nature.

[67]  J. Hurwitz,et al.  Inhibition of Nucleotide Excision Repair by the Cyclin-dependent Kinase Inhibitor p21 (*) , 1995, The Journal of Biological Chemistry.

[68]  M. Barbacid,et al.  To cycle or not to cycle: a critical decision in cancer , 2001, Nature reviews. Cancer.

[69]  T. Weinert,et al.  Toward maintaining the genome: DNA damage and replication checkpoints. , 2002, Annual review of genetics.

[70]  Mong-Hong Lee,et al.  Association of the Cyclin-dependent Kinases and 14-3-3 Sigma Negatively Regulates Cell Cycle Progression* , 2000, The Journal of Biological Chemistry.

[71]  K. Isselbacher,et al.  Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. , 1999, Science.

[72]  A. Mogilner,et al.  Cell division , 2003, Nature.

[73]  Isabelle Bedrosian,et al.  Cyclin E and survival in patients with breast cancer. , 2002, The New England journal of medicine.

[74]  J. A. Castillejo,et al.  5' CpG island hypermethylation is associated with transcriptional silencing of the p21(CIP1/WAF1/SDI1) gene and confers poor prognosis in acute lymphoblastic leukemia. , 2002, Blood.

[75]  L. Chin,et al.  The INK4a/ARF locus and melanoma , 2003, Oncogene.

[76]  T. Sandal Molecular aspects of the mammalian cell cycle and cancer. , 2002, The oncologist.

[77]  J. Ross,et al.  DNA ploidy and cell cycle analysis in cancer diagnosis and prognosis. , 1996, Oncology.

[78]  J. Bartek,et al.  Perspective: defects in cell cycle control and cancer , 1999 .

[79]  J F Barrett,et al.  Identification of CDK4 as a target of c-MYC. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[80]  W. Carroll,et al.  c-myc hypermutation in Burkitt's lymphoma. , 1992, Leukemia & lymphoma.

[81]  J. Takita,et al.  A new proliferation marker, minichromosome maintenance protein 2, is associated with tumor aggressiveness in esophageal squamous cell carcinoma , 2003, Journal of surgical oncology.

[82]  Jian Kuang,et al.  Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation , 1998, Nature Genetics.

[83]  Feng Jiang,et al.  Amplification/overexpression of a mitotic kinase gene in human bladder cancer. , 2002, Journal of the National Cancer Institute.

[84]  J. Kononen,et al.  Cyclin E overexpression and amplification in human tumours , 2003, The Journal of pathology.

[85]  N. Rhind,et al.  Cdc25 mitotic inducer targeted by chk1 DNA damage checkpoint kinase. , 1997, Science.

[86]  Hiroshi Katayama,et al.  The Aurora kinases: Role in cell transformation and tumorigenesis , 2003, Cancer and Metastasis Reviews.

[87]  J. Lunec,et al.  The role of the tumour suppressor p33ING1b in human neoplasia , 2003, Journal of clinical pathology.

[88]  C. Schlotter,et al.  C-myc, not HER-2/neu, can predict recurrence and mortality of patients with node-negative breast cancer , 2003, Breast Cancer Research.

[89]  P. Nurse A Long Twentieth Century of the Cell Cycle and Beyond , 2000, Cell.

[90]  J. Gerdes,et al.  The Ki‐67 protein interacts with members of the heterochromatin protein 1 (HP1) family: a potential role in the regulation of higher‐order chromatin structure , 2002, The Journal of pathology.

[91]  S. Tavtigian,et al.  Complex structure and regulation of the P16 (MTS1) locus. , 1995, Cancer research.

[92]  James M. Roberts,et al.  CDK inhibitors: positive and negative regulators of G1-phase progression. , 1999, Genes & development.

[93]  M. Serrano,et al.  A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma , 1995, Science.

[94]  A. Venkitaraman Breast Cancer Genes and DNA Repair , 1999, Science.

[95]  J. Cheville,et al.  p27kip1: a multifunctional cyclin-dependent kinase inhibitor with prognostic significance in human cancers. , 1999, The American journal of pathology.

[96]  L. Hartwell,et al.  Checkpoints: controls that ensure the order of cell cycle events. , 1989, Science.

[97]  Mong-Hong Lee,et al.  Regulators of G1 cyclin–dependent kinases and cancers , 2003, Cancer and Metastasis Reviews.

[98]  M. J. Ravitz,et al.  Cyclin-dependent kinase regulation during G1 phase and cell cycle regulation by TGF-beta. , 1997, Advances in cancer research.

[99]  Holly Neibergs,et al.  Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2 , 2004 .

[100]  J. Blow,et al.  Replication licensing — Origin licensing: defining the proliferative state? , 2002 .

[101]  Brian Schryver,et al.  A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers , 1998, The EMBO journal.

[102]  R. Abraham Cell cycle checkpoint signaling through the ATM and ATR kinases. , 2001, Genes & development.

[103]  C. Sherr The Pezcoller lecture: cancer cell cycles revisited. , 2000, Cancer research.

[104]  E. Harlow,et al.  The retinoblastoma tumour suppressor in development and cancer , 2002, Nature Reviews Cancer.

[105]  H. Lenz Clinical update: proteasome inhibitors in solid tumors. , 2003, Cancer treatment reviews.

[106]  R. Weinberg,et al.  Control of the cell cycle and apoptosis. , 1999, European journal of cancer.

[107]  T. Okamoto,et al.  Cdc25C interacts with PCNA at G2/M transition , 2002, Oncogene.

[108]  P. Steeg,et al.  Cyclins and breast cancer , 2004, Breast Cancer Research and Treatment.

[109]  P. Guldberg,et al.  Extensive intra- and interindividual heterogeneity of p15INK4B methylation in acute myeloid leukemia. , 1999, Cancer research.

[110]  J. A. Castillejo,et al.  CpG island hypermethylation is associated with transcriptional silencing of the p 21 CIP 1 / WAF 1 / SDI 1 gene and confers poor prognosis in acute lymphoblastic leukemia , 2002 .

[111]  J. Pietenpol,et al.  Cell-cycle dysregulation and anticancer therapy. , 2003, Trends in pharmacological sciences.

[112]  H. Mori,et al.  Centrosomal kinase AIK1 is overexpressed in invasive ductal carcinoma of the breast. , 1999, Cancer research.

[113]  Carsten Peterson,et al.  Predicting the future of breast cancer , 2003, Nature Medicine.